ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
MacroGenics halts trials of cancer drug after FDA partial hold
fiercebiotech
December 28, 2018Potential liver-related side effects have led to the FDA placing a partial clinical hold on a MacroGenics-developed bispecific antibody for cancer..... -
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody? Platform for Five Bispecific Antibody Programs for up to $450 Million
expressbpd
December 11, 2018WuXi Biologics and Oxford BioTherapeutics Ltd. announced the expansion of their strategic and innovative immuno-oncology (IO) alliance... -
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
en-cphi.cn
December 10, 2018WuXi Biologics announces a strategic collaboration with Brii Biosciences. -
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration
pharmafocusasia
December 04, 2018Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology..... -
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody? Platform for Three Bispecific Antibody Programs
Wuxi Biologics
September 27, 2018WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody? Platform to develop three bispecific antibodies.
Pharma Sources Insight July 2025
